bioAffinity Technologies (NASDAQ:BIAF) Releases Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) released its earnings results on Friday. The company reported ($0.81) earnings per share for the quarter, FiscalAI reports. bioAffinity Technologies had a negative return on equity of 301.67% and a negative net margin of 241.93%.The business had revenue of $1.35 million during the quarter.

bioAffinity Technologies Stock Down 3.0%

Shares of BIAF traded down $0.06 during trading hours on Friday, hitting $2.06. The company had a trading volume of 114,928 shares, compared to its average volume of 6,211,234. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.58 and a current ratio of 2.60. The stock has a market capitalization of $9.26 million, a price-to-earnings ratio of -0.13 and a beta of -1.19. bioAffinity Technologies has a 52-week low of $0.69 and a 52-week high of $15.00. The firm has a fifty day moving average price of $2.60 and a 200-day moving average price of $1.90.

Institutional Trading of bioAffinity Technologies

Several institutional investors have recently added to or reduced their stakes in the business. Sabby Management LLC bought a new stake in shares of bioAffinity Technologies in the 3rd quarter worth $719,000. J. Safra Sarasin Holding AG purchased a new stake in shares of bioAffinity Technologies during the first quarter valued at $164,000. Geode Capital Management LLC purchased a new stake in shares of bioAffinity Technologies during the fourth quarter valued at $36,000. Finally, Scientech Research LLC bought a new stake in bioAffinity Technologies in the 3rd quarter worth about $49,000. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BIAF shares. Weiss Ratings lowered shares of bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Wall Street Zen upgraded shares of bioAffinity Technologies to a “hold” rating in a report on Saturday, April 4th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, bioAffinity Technologies has an average rating of “Sell”.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.